Premium Nahrungsergänzungsmittel | artgerecht

Fremanezumab - CGRP Antibody for Migraine Prevention

Fremanezumab is a monoclonal antibody used for the preventive treatment of migraine in adults. It targets calcitonin gene-related peptide (CGRP) to reduce the frequency and severity of migraine attacks.

Regular tips about health Regular tips about health

Things worth knowing about "Fremanezumab"

Fremanezumab is a monoclonal antibody used for the preventive treatment of migraine in adults. It targets calcitonin gene-related peptide (CGRP) to reduce the frequency and severity of migraine attacks.

What is Fremanezumab?

Fremanezumab is a humanized monoclonal antibody approved for the preventive (prophylactic) treatment of migraine in adults. It is marketed under the brand name Ajovy and has received approval from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The drug specifically targets calcitonin gene-related peptide (CGRP), a neuropeptide that plays a key role in triggering migraine attacks. Fremanezumab is administered as a subcutaneous (under-the-skin) injection and is approved for both episodic and chronic migraine.

Mechanism of Action

CGRP is a neuropeptide released from trigeminal nerve endings during migraine attacks. It causes blood vessel dilation and amplifies pain signaling in the nervous system. Fremanezumab binds directly to CGRP itself (rather than its receptor), neutralizing its activity. This blockade leads to:

Reduced transmission of pain signals,
Decreased dilation of cranial blood vessels,
Diminished neurogenic inflammation in the trigeminal system.

As a result, the frequency, duration, and intensity of migraine attacks are significantly reduced.

Indications

Fremanezumab is indicated for adults suffering from episodic migraine (fewer than 15 migraine days per month) or chronic migraine (15 or more headache days per month, at least 8 of which fulfill migraine criteria). It is typically prescribed when at least two prior preventive migraine therapies have failed or were not tolerated.

Dosage and Administration

Fremanezumab is delivered via subcutaneous injection. Two dosing options are available:

Monthly dosing: 225 mg once per month
Quarterly dosing: 675 mg (three injections of 225 mg each) every three months

Injections are given in the abdomen, thigh, or upper arm. After proper training, patients may self-administer the injection. Regular follow-up visits with a healthcare provider are recommended to monitor treatment response.

Side Effects

Fremanezumab is generally well tolerated. The most commonly reported side effects are local injection site reactions, including:

Redness (erythema)
Swelling (edema)
Pain or burning sensation
Hardening of the skin (induration)

Systemic reactions such as allergic or hypersensitivity responses are rare but possible. Patients with known hypersensitivity to fremanezumab or any of its excipients should not use this medication.

Contraindications and Precautions

Fremanezumab should not be used in patients with:

Known hypersensitivity to the active substance or excipients
Pregnancy or breastfeeding (use only after careful risk-benefit assessment)

Limited data are available for patients with severe renal or hepatic impairment. Medical consultation is essential in these situations.

Clinical Efficacy

The HALO clinical trial program demonstrated that fremanezumab significantly reduced the monthly number of migraine days in patients with both episodic and chronic migraine. A clinically meaningful response, defined as a reduction of at least 50 percent in monthly migraine days, was achieved in a substantial proportion of patients. Onset of efficacy was observed as early as the first month of treatment.

References

Silberstein SD et al. - Fremanezumab for the Preventive Treatment of Chronic Migraine. New England Journal of Medicine, 2017; 377: 2113-2122.
European Medicines Agency (EMA) - Product Information: Ajovy (Fremanezumab), last updated 2023. Available at: https://www.ema.europa.eu
Dodick DW et al. - ARISE: A Phase 3 Randomized Trial of Erenumab for Episodic Migraine. Cephalalgia, 2018; 38(6): 1026-1037. (Comparative context for CGRP-targeted therapies)

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.